Talphera (TLPH) Net Equity Issued and Repurchased (2010 - 2023)
Talphera's (TLPH) quarterly Net Equity Issued and Repurchased came in at -$68000.0 in Q4 2023, down 134.0% quarter-over-quarter from $200000.0 in Q3 2022.
Talphera (TLPH) Net Equity Issued and Repurchased (2010 - 2023) Analysis & Trends
Talphera's Net Equity Issued and Repurchased history runs 10 years deep, the most recent figure standing at -$68000.0 for Q4 2023.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$68000.0 in Q4 2023; TTM through Dec 2024 was $132000.0, a 0.0% change from a year earlier, with the FY2023 full-year figure at $8.9 million, up 3605.44% from the prior year.
- Net Equity Issued and Repurchased declined to -$68000.0 in Q4 2023 per TLPH's latest filing, from $200000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $36.4 million in Q1 2021 and bottomed at -$36.4 million in Q3 2021.
- The 5-year median for Net Equity Issued and Repurchased is $1.0 million (2019), against an average of $3.0 million.
- Biggest YoY gain for Net Equity Issued and Repurchased was 4537.76% in 2021; the steepest drop was 465.39% in 2021.
- Year by year, Net Equity Issued and Repurchased stood at $1.2 million in 2019, then jumped by 705.92% to $9.9 million in 2020, then plunged by 465.91% to -$36.4 million in 2021, then soared by 100.55% to $200000.0 in 2022, then tumbled by 134.0% to -$68000.0 in 2023.
- Per Business Quant, the three latest TLPH Net Equity Issued and Repurchased figures stand at -$68000.0 (Q4 2023), $200000.0 (Q3 2022), and -$36.4 million (Q3 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -68,000.00 |
| Dec 31, 2023 | -68,000.00 |
| Sep 30, 2022 | 200,000.00 |
| Sep 30, 2022 | 200,000.00 |
| Sep 30, 2021 | -36.36 Mn |
| Sep 30, 2021 | -36.36 Mn |
| Jun 30, 2021 | 7.50 Mn |
| Jun 30, 2021 | 7.50 Mn |
| Mar 31, 2021 | 36.36 Mn |
| Mar 31, 2021 | 36.36 Mn |
| Dec 31, 2020 | 9.94 Mn |
| Dec 31, 2020 | 9.94 Mn |
| Sep 30, 2020 | 9.95 Mn |
| Sep 30, 2020 | 9.95 Mn |
| Jun 30, 2020 | 665,000.00 |
| Jun 30, 2020 | 665,000.00 |
| Mar 31, 2020 | 784,000.00 |
| Mar 31, 2020 | 784,000.00 |
| Sep 30, 2019 | 1.23 Mn |
| Sep 30, 2019 | 1.23 Mn |